Methylaminolaevulinic acid photodynamic therapy in the treatment of erythroplasia of Queyrat by Feldmeyer, L et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2011
Methylaminolaevulinic acid photodynamic therapy in the treatment of
erythroplasia of Queyrat
Feldmeyer, L; Krausz-Enderlin, V; Töndury, B; Hafner, J; French, L E; Hofbauer, G F L
Abstract: BACKGROUND: Erythroplasia of Queyrat (EQ) is an intra-epithelial carcinoma of the penis.
Progression to invasive carcinoma may occur. Its cause is unknown but some evidence suggests infection
with human papillomavirus in the pathogenesis of EQ; however, recent data do not confirm this. Therapy
is difficult and associated with important recurrence rates. Photodynamic therapy (PDT) employs a
photosensitizer excited by visible light. The resulting photodynamic reaction selectively destroys atypical
cells. Only few reports exist on the use of topical PDT in the treatment of EQ. OBJECTIVE: We report
11 cases of EQ treated by topical methylaminolaevulinic acid (MAL) PDT. RESULTS: Out of 11 male
patients with EQ treated by topical MAL-PDT, 3 achieved complete remission sustained for 24 and 51
months and 4 a partial remission sustained for 2-45 months with a follow-up period of 4-45 months (1
patient lost to follow-up); surprisingly, 2 of the 4 patients with partial remission presented a complete
remission after 20 and 45 months of follow-up, respectively, without further therapy. Four patients
showed progression of the disease. CONCLUSION: Whereas topical MAL-PDT offers the advantages of
tumour specificity, preservation of function and a good cosmetic result, side effects may cause treatment
discontinuation in some cases. Treatment of EQ with PDT may represent a valuable option in selected
cases, but our data do not allow considering it as a first-line therapeutic option.
DOI: 10.1159/000330328
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-58274
Published Version
Originally published at:
Feldmeyer, L; Krausz-Enderlin, V; Töndury, B; Hafner, J; French, L E; Hofbauer, G F L (2011). Methy-
laminolaevulinic acid photodynamic therapy in the treatment of erythroplasia of Queyrat. Dermatology,
223(1):52-56. DOI: 10.1159/000330328
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
 Original Paper 
 Dermatology 2011;223:52–56 
 DOI: 10.1159/000330328 
 Methylaminolaevulinic Acid 
Photodynamic Therapy in the Treatment 
of Erythroplasia of Queyrat 
 Laurence Feldmeyer    Valérie Krausz-Enderlin    Bettina Töndury    Jürg Hafner    
Lars E. French    Günther F.L. Hofbauer 
 Dermatology Department, University Hospital Zürich,  Zürich , Switzerland 
may cause treatment discontinuation in some cases. Treat-
ment of EQ with PDT may represent a valuable option in se-
lected cases, but our data do not allow considering it as a 
first-line therapeutic option.  Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Erythroplasia of Queyrat (EQ) was originally de-
scribed by Tarnovsky in 1891. It was some 20 years later 
that the French dermatologist Queyrat carried out more 
detailed studies delineating this condition as a distinct 
entity  [1] . EQ is an intra-epithelial carcinoma of the penis 
and represents an in-situ form of squamous cell carci-
noma. Infection with oncogenic human papillomavirus-
es can be demonstrated in the great majority of cases  [2] , 
although a recent study cast doubt on this, showing ab-
sence of PCR-detectable human papillomavirus in EQ in 
11 patients; further investigations are needed in order to 
confirm the role of human papillomavirus in delineating 
this risk  [3] . Clinically, these lesions present as single or 
multiple, erythematous, sharply demarcated often vel-
vety, shiny plaques. Progression to invasive squamous 
carcinoma may occur in up to 30%  [2, 4] . Surgery is the 
gold standard therapy for EQ. Generally, a surgical ap-
proach is more reliable in terms of clinical and histologi-
cal resolution, but as it is an invasive method, one should 
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 Abstract 
 Background: Erythroplasia of Queyrat (EQ) is an intra-epi-
thelial carcinoma of the penis. Progression to invasive carci-
noma may occur. Its cause is unknown but some evidence 
suggests infection with human papillomavirus in the patho-
genesis of EQ; however, recent data do not confirm this. 
Therapy is difficult and associated with important recur-
rence rates. Photodynamic therapy (PDT) employs a photo-
sensitizer excited by visible light. The resulting photody-
namic reaction selectively destroys atypical cells. Only few 
reports exist on the use of topical PDT in the treatment of EQ. 
 Objective: We report 11 cases of EQ treated by topical me-
thylaminolaevulinic acid (MAL) PDT.  Results: Out of 11 male 
patients with  EQ treated by topical MAL-PDT, 3 achieved 
complete remission sustained for 24 and 51 months and 4 a 
partial remission sustained for 2–45 months with a follow-up 
period of 4–45 months (1 patient lost to follow-up); surpris-
ingly, 2 of the 4 patients with partial remission presented a 
complete remission after 20 and 45 months of follow-up, re-
spectively, without further therapy. Four patients showed 
progression of the disease.  Conclusion: Whereas topical 
MAL-PDT offers the advantages of tumour specificity, pres-
ervation of function and a good cosmetic result, side effects 
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take into consideration cosmetic and functional de-
mands. Mohs micrographic surgery is favoured because 
it precisely identifies tumour-free margins while sparing 
normal tissue, thus optimizing cosmetic and functional 
outcomes  [5–7] . In our patients, photodynamic therapy 
(PDT) was chosen either because of a previous failure of 
topical therapy (imiquimod, 5-fluorouracil) or in case of 
recurrence after surgery, when the patient declined re-
peat surgery, as well as first-line therapy in 5 patients.
 Photodynamic Treatment Protocol of the Glans Penis 
 Methylaminolaevulinate 160 mg/g of vehicle (MAL) 
was applied for 3 h under an occlusive dressing to the 
glans penis covering the affected area as well as a 5-mm 
margin of clinically normal surrounding tissue. Before il-
lumination, a local anaesthetic penile ring block using 2% 
lidocaine without adrenalin was applied. The affected ar-
eas were then illuminated using a non-coherent red light 
source (Waldmann  PDT 1200L, 570–670 nm) with a to-
tal dose of 75 J/cm 2 . The therapeutic response was evalu-
ated clinically at regular intervals as well as by fluores-
cence dynamic diagnosis (FDD) in a subgroup of patients.
 Case Reports 
 A total of 11 patients with EQ affecting the glans penis were 
treated by PDT. The patients’ characteristics are summarized in 
 table 1 . In all cases the diagnosis was confirmed by histology be-
fore PDT. In some cases, the clinical follow-up was documented 
with photographs ( fig. 1 ).
Table 1. D etails of the patients presenting with EQ
Pa-
tient
Age at
diag-
nosis
(years)
Previous
treatment
before PDT
Number
of PDT
sessions
Adverse events Interval
between
treatments
(weeks)
Primary
clinical
outcome
after PDT
FDD primary
outcome
Recurrence-
free follow-up
months after
last PDT
Further
treatment
Outcome
1 49 imiquimod,
5-fluorouracil,
circumcision
11 none 1–48 complete
remission
no specific
enhancement
51 none complete remission 
(51)
2 61 imiquimod,
circumcision
7 erythema, dysuria 1–20 complete
remission
no specific
enhancement
24 none complete remission 
(24)
3 65 none 19 redness, swelling, 
dysuria, haematoma
1–10 complete
remission
n.d. 1.5 none complete remission 
(h.c.) (1.5)
4 77 CO2 laser,
circumcision
16 none 1–6 partial
remission 
n.d. 2 radiotherapy complete
remission (4)
5 87 none 8 none 1–7 partial
remission
stationary (iso-
lated  fluores-
cent macula)
n.d.
(patient lost
to follow-up)
n.d.
(patient lost
to follow-up)
n.d.
(patient lost
to follow-up)
6 70 none 5 after 5th treatment 
redness, swelling
and pain of gland
1 partial
remission 
n.d. 20 none complete remission 
(h.c.) (20)
7 71 imiquimod,
circumcision
12 erythema, dysuria 
(once)
1–11 partial
remission
no specific
enhancement
45 none complete remission 
(45)
8 83 none 2 painful inflammatory 
reaction
1 progression n.d. 12 CO2 laser complete remission 
(16)
9 51 imiquimod 3 n.d n.d progression n.d. 6 CO2 laser recurrence (12)
10 65 5-fluorouracil,
imiquimod
2 n.d. 8 progression n.d. 6 radiotherapy,
CO2 laser,
circumcision
complete remission 
(17)
11 80 none 4 painful inflammatory 
reaction
2 progression n.d. 0 radiotherapy –
F igures in parentheses indicate months of total follow-up after last PDT. n.d. = Not determined; h.c. =  histologically confirmed.
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 All male patients were aged 49–87 years at diagnosis (mean 
69 years). For 5 patients, PDT was the first-line treatment (pa-
tients No. 3, 5, 6, 8 and 11), while the other patients had already 
undergone treatment with topical imiquimod (patients 1, 2, 7, 9 
and 10), topical 5-fluorouracil (patients 1 and 10), carbon dioxide 
laser (patient 4) or circumcision (patient 1, 2, 4 and 7). The pa-
tients underwent between 2 and 19 PDT treatment sessions 
(mean 8 sessions). The interval between 2 sessions varied from 1 
to 48 weeks.
 Out of 11 patients, 3 achieved a long-term complete response 
sustained for 24 and 51 months (patients 1–3), respectively, and 4 
a partial remission (patients 4–7, clinically residual small red 
plaque) sustained for 2–45 months with a follow-up period of 
4–45 months (1 patient lost to follow-up). Histological confirma-
tion of remission was obtained in 2 cases (patients 3 and 6). It is 
noteworthy that 2 of the 3 patients with complete remission had 
been resistant to previous treatments. Surprisingly, 2 of the 4 pa-
tients with partial remission after PDT (patients 6 and 7) present-
ed a complete remission after 20 and 45 months of follow-up, re-
spectively, without further therapy. Retrospectively, as no con-
firmation biopsy was performed immediately after the end of 
treatment in these patients, the redness interpreted as residual 
disease may have been only a side effect of therapy. Four patients 
showed a progression (patients 9 and 10) or did not tolerate the 
therapy (patients 8 and 11). Five patients required another thera-
peutic modality subsequently (patients 4 and 8–11). FDD was used 
in 4 patients (patients 1, 2, 5 and 7) and compared to the clinical 
evaluation of residual disease. FDD correlated only partly with 
the clinical assessment: in the 4 patients where FDD was per-
formed, 3 showed a correlation with the clinical status whereas in 
patient 7, FDD showed no fluorescence while a red macula was 
clinically visible on his mucosa. In 2 cases (patients 3 and 6), a bi-
opsy was performed just after, respectively, at a distance to the end 
of therapy because of a suspicion of recurrence: neither histology 
showed signs of malignant transformation. This suggests that the 
evaluation of the outcome is clinically difficult.
 The mean number of PDT sessions was 12.3 in the complete 
response, 10.3 in the partial remission group, whereas it was only 
2.8 in the progression group.
 Most patients experienced erythema and mild to moderate 
burning at the site of application during illumination, followed by 
mild swelling. Reported adverse effects included discomfort as-
sociated with dysuria, which subsided over the following 1–3 days 
before it resolved completely (patients 2, 3, 6 and 7). Haematoma 
at the site of PDT was reported by patient No. 3. Patients 8 and 11 
had to stop PDT because of adverse events: both had a very pain-
ful inflammatory reaction after 2 sessions. Three patients (No. 1, 
4 and 5) reported no adverse events. No information on adverse 
events was available for 2 patients (No. 9 and 10).
Patient 3
Patient 5
Patient 6
Patient 11
 Fig. 1. Clinical pictures before (left) and after (right) PDT in pa-
tients No. 3, 5, 6 (partial remission) and 11 (progression). 
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e Table 2.  Treatment modalities for EQ as reported in the literature
Modality Reference No.
PDT 8
Electrocautery and curettage 9
5-Fluorouracil cream 10
Imiquimod cream 11–14
Isotretinoin 15
Cryotherapy 16, 17
Laser ablation 18–21
Radiotherapy 22–24
Circumcision 5, 25
Local excision 5
Mohs surgery 5–7
Total glans resurfacing 26
Cidofovir 27
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 Discussion 
 The treatment options for EQ reported in the liter-
ature are numerous as listed in  table  2 . MAL-based
PDT – depending on the country – is a registered treat-
ment for superficial basal cell carcinoma, Bowen’s disease 
and actinic keratosis and a reported treatment option for 
squamous cell carcinoma  [28] . Topical MAL-PDT com-
bines MAL, which is converted into protoporphyrin IX 
within cells, and visible light to produce a photodynamic 
effect in the presence of oxygen, resulting in the forma-
tion of cytotoxic reactive oxygen species. It leads to a se-
lective destruction of abnormal cells while preserving 
normal cells and results in an excellent cosmetic out-
come. PDT is a highly effective therapy for the treatment 
of Bowen’s disease, a carcinoma in situ affecting the out-
er skin and similar in histology and presentation to EQ 
with complete remission in approximately 90% of pa-
tients treated and partial remission in 7.5% of patients 
treated  [29, 30] .
 We present 11 patients with EQ who were treated by 
topical MAL-PDT. Of 11 patients, 3 achieved a complete 
response, 4 a partial remission, and 4 had a progression 
of disease. Whereas 5 patients required a subsequent 
therapeutic modality following MAL-PDT, PDT was a 
very satisfactory therapy for 5 other patients (1 patient 
lost to follow-up). Of note, the 4 patients who underwent 
circumcision before PDT seemingly showed a better out-
come with 2 complete and 2 partial remissions. Others 
have reported on the use of PDT in EQ with similar re-
sults: Stables et al.  [8]  reported 4 patients with EQ treated 
by topical 5-aminolaevulinic acid PDT. Of 2 patients with 
limited disease, 1 achieved a long-term complete response 
(36 months) after a single cycle of treatment and the oth-
er remained free of disease for 18 months after the second 
treatment. Two further patients with more extensive dis-
ease achieved partial response after 2 cycles of 5-amino-
laevulinic acid PDT and required laser vaporization  [8] . 
Lee and Ryman [9] reported an 82-year-old patient with 
invasive squamous cell carcinoma of the glans penis aris-
ing in EQ. While he underwent Mohs micrographic sur-
gery for his invasive carcinoma, his residual EQ was treat-
ed by PDT. Eighteen weeks after completion of one cycle 
of treatment, he had no evidence of recurrence  [9] .
 Although the small number of reported cases (5 pa-
tients to date  [8, 9] ) does not allow a relevant statistical 
comparison of the success of this therapy, our results doc-
ument a favourable outcome after PDT for some of the 
patients and underline the importance of repeated treat-
ment. Indeed, the mean number of PDT sessions in our 
patient collective was 12.3 in the complete response 
group, 10.3 in the partial remission group, whereas it was 
only 2.8 in the progression group. The patients of Stables 
et al.  [8] had 1–2 cycles, that of Lee and Ryman  [9] 1 cycle 
of therapy only. We think therefore that the success of the 
PDT therapy for EQ is closely linked to the number of 
sessions, and that patients treated by this method need to 
be regularly followed clinically. We believe that PDT pro-
vides a valuable option for selected cases like patients en-
countering recurrence after surgery, or in patients where 
conservative treatment is preferred to surgery. The main 
advantages of PDT are the good tolerability with limited 
adverse events in comparison to more invasive treat-
ments  [31] as well as the good cosmetic result. Neverthe-
less, side effects may cause treatment discontinuation in 
some cases. The main drawbacks are the high recurrence 
rate which mandates a regular clinical follow-up as well 
as the time-consuming treatment.
 Conclusion 
 There have only been few reports on 5-aminolaevu-
linic acid -PDT in the treatment of EQ. We provide here 
clinical data on MAL-PDT for EQ as a viable treatment 
for half of our 11 patients. However, complete remission 
immediately after therapy has been achieved in 3 patients 
only. Two of the 4 patients with partial remission after 
PDT presented a complete remission at the follow-up, 
without further therapy. The redness interpreted as re-
sidual disease may have been only a side effect of therapy. 
Four patients were non-responders, requiring further 
treatment.
 Our results indicate that treatment of EQ with MAL-
PDT may represent a valuable option in selected cases of 
histologically confirmed EQ, with preserved function 
and good cosmetic outcome. However, our data do not 
allow considering it as a first-line therapeutic recommen-
dation. Data from the literature also report inconsistent 
success. In conclusion, PDT may have a favourable out-
come for some patients with EQ, but long-term efficacy 
and safety should be assessed on a larger clinical basis. 
Long-term follow-up is important to recognize and treat 
relapses at an early time point.
 Disclosure Statement 
 The authors have no conflicts of interest.
 
 Feldmeyer/Krausz-Enderlin/Töndury/
Hafner/French/Hofbauer 
Dermatology 2011;223:52–56 56
 References 
 1 Queyrat L: Erythroplasie du gland. Bull Soc 
Fr Dermatol Syphiligr 1911; 22: 378–382. 
 2 Wieland U, Jurk S, Weissenborn S, Krieg T, 
Pfister H, Ritzkowsky A: Erythroplasia of 
Queyrat: coinfection with cutaneous carci-
nogenic human papillomavirus type 8 and 
genital papillomaviruses in a carcinoma in 
situ. J Invest Dermatol 2000; 115: 396–401. 
 3 Nasca MR, Potenza MC, Alessi L, Paravizzi-
ni G, Micali G: Absence of PCR-detectable 
human papilloma virus in erythroplasia of 
Queyrat using a comparative control group. 
Sex Transm Infect 2011; 86: 199–201. 
 4 Malek RS: Laser treatment of premalignant 
and malignant squamous cell lesions of the 
penis. Lasers Surg Med 1992; 12: 246–253. 
 5 Bunker CB: Topics in penile dermatology. 
Clin Exp Dermatol 2001; 26: 469–479. 
 6 Mohs FE, Snow SN, Larson PO: Mohs micro-
graphic surgery for penile tumors. Urol Clin 
North Am 1992; 19: 291–304. 
 7 Brown MD, Zachary CB, Grekin RC, Swan-
son NA: Penile tumors: their management by 
Mohs micrographic surgery. J Dermatol Surg 
Oncol 1987; 13: 1163–1167. 
 8 Stables GI, Stringer MR, Robinson DJ, Ash 
DV: Erythroplasia of Queyrat treated by top-
ical aminolaevulinic acid photodynamic 
therapy. The British journal of dermatology 
1999; 140: 514–517. 
 9 Lee MR, Ryman W: Erythroplasia of Quey-
rat treated with topical methyl aminolevu-
linate photodynamic therapy. Australas J 
Dermatol 2005; 46: 196–198. 
 10 Goette DK, Carson TE: Erythroplasia of 
Quey rat: treatment with topical 5-fluoro-
uracil. Cancer 1976; 38: 1498–1502. 
 11 Arlette JP: Treatment of Bowen’s disease and 
erythroplasia of Queyrat. Br J Dermatol 
2003; 149(suppl 66):43–49. 
 12 Micali G, Nasca MR, De Pasquale R: Eryth-
roplasia of Queyrat treated with imiquimod 
5% cream. J Am Acad Dermatol 2006; 55: 
 901–903. 
 13 Orengo I, Rosen T, Guill CK: Treatment of 
squamous cell carcinoma in situ of the penis 
with 5% imiquimod cream: a case report. J 
Am Acad Dermatol 2002; 47:S225–228. 
 14 Danielsen AG, Sand C, Weismann K: Treat-
ment of Bowen’s disease of the penis with im-
iquimod 5% cream. Clin Exp Dermatol 2003; 
 28(suppl 1):7–9. 
 15 Harrington KJ, Price PM, Fry L, Witherow 
RO: Erythroplasia of Queyrat treated with 
isotretinoin. Lancet 1993; 342: 994–995. 
 16 Sonnex TS, Ralfs IG, Plaza de Lanza M, Daw-
ber RP: Treatment of erythroplasia of Quey-
rat with liquid nitrogen cryosurgery. Br J 
Dermatol 1982; 106: 581–584. 
 17 Colver GB, Dawber RP: Cryosurgery – the 
principles and simple practice. Clin Exp 
Dermatol 1989; 14: 1–6. 
 18 Van Bezooijen BP, Horenblas S, Meinhardt 
W, Newling DW: Laser therapy for carcino-
ma in situ of the penis. J Urol 2001; 166: 1670–
1671. 
 19 Rosemberg SK, Fuller TA: Carbon dioxide 
rapid superpulsed laser treatment of eryth-
roplasia of Queyrat. Urology 1980; 16: 181–
182. 
 20 Conejo-Mir JS, Munoz MA, Linares M, Ro-
driguez L, Serrano A: Carbon dioxide laser 
treatment of erythroplasia of Queyrat: a re-
visited treatment to this condition. J Eur 
Acad Dermatol Venereol 2005; 19: 643–644. 
 21 Greenbaum SS, Glogau R, Stegman SJ, Tro-
movitch TA: Carbon dioxide laser treatment 
of erythroplasia of Queyrat. J Dermatol Surg 
Oncol 1989; 15: 747–750. 
 22 Blank AA, Schnyder UW: Soft-X-ray therapy 
in Bowen’s disease and erythroplasia of
Queyrat. Dermatologica 1985; 171: 89–94. 
 23 Davis-Daneshfar A, Trueb RM: Bowen’s dis-
ease of the glans penis (erythroplasia of
Queyrat) in plasma cell balanitis. Cutis 2000; 
 65: 395–398. 
 24 Grabstald H, Kelley CD: Radiation therapy 
of penile cancer: six to ten-year follow-up. 
Urology 1980; 15: 575–576. 
 25 Mikhail GR: Cancers, precancers, and pseu-
docancers on the male genitalia. A review of 
clinical appearances, histopathology, and 
management. J Dermatol Surg Oncol 1980; 6: 
 1027–1035. 
 26 Hadway P, Corbishley CM, Watkin NA: To-
tal glans resurfacing for premalignant le-
sions of the penis: initial outcome data. BJU 
Int 2006; 98: 532–536. 
 27 Calista D: Topical cidofovir for erythroplasia 
of Queyrat of the glans penis. Br J Dermatol 
2002; 147: 399–400. 
 28 Kalka K, Merk H, Mukhtar H: Photodynam-
ic therapy in dermatology. J Am Acad Der-
matol 2000; 42: 389–413, quiz 414–386. 
 29 Kennedy JC, Pottier RH, Pross DC: Photody-
namic therapy with endogenous protopor-
phyrin IX: basic principles and present clini-
cal experience. J Photochem Photobiol 1990; 
 6: 143–148. 
 30 Cairnduff F, Stringer MR, Hudson EJ, Ash 
DV, Brown SB: Superficial photodynamic 
therapy with topical 5-aminolaevulinic acid 
for superficial primary and secondary skin 
cancer. Br J Cancer 1994; 69: 605–608. 
 31 Nobbe S, Trueb RM, French LE, Hofbauer 
GF: Herpes simplex virus reactivation as
a complication of photodynamic therapy. 
Photodermatol Photoimmunol Photomed 
2011; 27: 51–52. 
 
